Discover the latest breakthroughs, partnerships, and insights from PepKon. Innovation moves fast—don’t miss a beat.
Taking Pepkon's peptide expertise to JPM 2025. Connecting, innovating, and shaping the future of biotech.
Driving innovation in peptide therapeutics, PepKon secures a spot among Europe’s top biotech start-ups in the prestigious EIT Health Catapult program.
PepKon is ready to build powerful partnerships at BIO-Europe 2024, driving progress in biotech and pharma.
PepKon was honored to be among the 12 finalists at the MEET2WIN 2024 convention, organized by MATWIN. As a biotech company specializing in peptide-based oncology treatments, we presented our latest research advancements to Matwin's board.
PepKon participated in NETVA 2024 Immersion Week in Boston, organized by the Consulate General of France in Boston and Business France Healthcare - North America. This event provided a unique opportunity to explore Boston’s biotech ecosystem and highlight our innovations in peptide-based oncology treatments.
PepKon is honored to be selected to present at the Onco Startup Summit 2024, an exclusive event during the IFODS Congress in Paris. This platform will allow us to showcase our advancements in peptide-based oncology treatments to a distinguished audience of oncologists, investors, and industry experts.
PepKon is proud to be among the seven innovative projects selected by the PSCC to receive specialized support in advancing groundbreaking cancer therapies. This recognition reinforces our commitment to pioneering peptide-based oncology treatments.
PepKon is proud to be awarded the VCLS Neighborhood Startup Award, recognizing our pioneering work in peptide-based oncology treatments. This prestigious program will provide us with expert mentorship, strategic guidance, and access to a global network of industry leaders
